For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Opdivo Best-Selling Drug in Japan for 8 Months on End: Encise
September 7, 2022
- Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
- Tatsumi Kagaku Likely to Halt Shipments of 46 Products after Administrative Penalty
September 6, 2022
- Moderna to File BA.4/5-Targeting Booster Jab in Japan
September 6, 2022
- Teijin Gets Approval for 14-Day Version of Osteoporosis Med Ostabalo
September 6, 2022
- Leo Pharma Japan Names Finance Head Kook Hyun Son as Interim Chief
September 2, 2022
- Nitrosamine Impurity Detected in Sitagliptin, Shipments in Japan to Continue with FDA-Set Limit: MSD/Ono
September 2, 2022
- CureApp’s Hypertension Therapeutic App Rolls Out with Insurance Coverage
September 2, 2022
- AstraZeneca Japan Sets Up New Biz Unit for Vaccines and Immune Therapies
September 2, 2022
- Daiichi Sankyo Begins PIII Primary Dose Study for mRNA COVID Jab
September 2, 2022
- Pfizer Discussing Filing of BA.5-Based Vaccine with Japanese Authorities
September 1, 2022
- Servier to Bolster Japan Business with Focus on Oncology: President Laureau
September 1, 2022
- Pfizer Japan to Curb Shipments and Recall Amoxapine over Carcinogen Risks
September 1, 2022
- Nobelpharma Makes Global Debut with US Launch of Hyftor
September 1, 2022
- BMS, Nagoya University Tie Up for Innovative Drug Discovery
August 31, 2022
- Eisai Files New Injection Formulation of Fycompa in Japan
August 31, 2022
- Novo Seeks Japan Approval of Hemophilia Drug Concizumab
August 31, 2022
- Viatris Launches Japan PIII to Add GAD Indication for Effexor SR
August 31, 2022
- Taiho’s GIST Drug Jeselhy Now Available in Japan
August 31, 2022
- Daiichi Sankyo Files Vanflyta for Frontline AML in Japan
August 31, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…